Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.47 |
| ▸ | FECH | P22830 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL216565 | 0.87 | EGFR (0.55) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL2736365 | 0.86 | EGFR (0.50) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL216405 | 0.86 | EGFR (0.50) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL218431 | 0.81 | ERBB2 (0.50) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL4468668 | 0.78 | EGFR (0.67) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL6846207 | 0.77 | EGFR (0.59) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL218430 | 0.74 | ERBB2 (0.54) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL2760082 | 0.74 | ERBB2 (0.54) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL4866251 | 0.74 | EGFR (0.67) | EGFRHDAC1HDAC6ERBB2FECH | |
| SCHEMBL2736366 | 0.74 | ERBB2 (0.54) | EGFRHDAC1HDAC6ERBB2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7488823-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1567506-A4 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA INC (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1567506-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | Array Biopharma, Inc. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | EGFR 3/4885HDAC1 3901/4885HDAC6 3777/4885 |
| US-20050101617-A1 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ERBB2, GRB2, EGFR | EGFR 3/4885HDAC1 3901/4885HDAC6 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.